Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 May;96(2):323–328. doi: 10.1111/j.1365-2249.1994.tb06561.x

Modulation of the IL-2 production defect in vitro in Graves' disease.

Z Eisenstein 1, E Engelsman 1, M Weiss 1, Y Kalechman 1, B Sredni 1
PMCID: PMC1534893  PMID: 8187341

Abstract

IL-2 production by mitogen-induced peripheral blood mononuclear cells was reported to be reduced in several autoimmune diseases, including Graves' disease (GD). This production defect in hyperthyroid GD was restored to normal by antithyroid drug therapy or during remission. However, its underlying mechanism and role in the autoimmune process are still uncertain. The present study was undertaken in order to screen the in vitro IL-2 generating system for putative factors responsible for its failure, and to see to what extent this was reversible. Thyroid hormone or antithyroid drugs had no effect on IL-2 production in vitro. Cultures were found to be free of soluble inhibitors of IL-2 production or action. IL-1 deficiency as a cause of the IL-2 defect was ruled out; rather, Graves' adherent cells were found to be activated in being capable of secreting large amounts of IL-1 and prostaglandin E2 (PGE2). The latter was not found to be responsible for the decreased IL-2 production. IL-2 production by Graves' mononuclears was completely restored to normal by: (i) adherent cell depletion, irradiation or substitution with normal adherent cells; (ii) preincubation of mononuclears for 24-72 h before mitogen stimulation; (iii) the synergistic action of a phorbol ester and a calcium ionophore. These data indicate that inhibition by activated adherent cells accounts for the in vitro IL-2 production defect in GD. This inhibition is not mediated by soluble factors, but probably through direct interaction with the producing cells, and is reversible in rested cultures or through a bypassed signal transduction.

Full text

PDF
323

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmann A. J., Burman K. D. The role of T lymphocytes in autoimmune thyroid disease. Endocrinol Metab Clin North Am. 1987 Jun;16(2):287–326. [PubMed] [Google Scholar]
  2. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982 Jun;69(6):1388–1392. doi: 10.1172/JCI110579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bagnasco M., Venuti D., Prigione I., Torre G. C., Ferrini S., Canonica G. W. Graves' disease: phenotypic and functional analysis at the clonal level of the T-cell repertoire in peripheral blood and in thyroid. Clin Immunol Immunopathol. 1988 May;47(2):230–239. doi: 10.1016/0090-1229(88)90075-x. [DOI] [PubMed] [Google Scholar]
  4. Chouaib S., Chatenoud L., Klatzmann D., Fradelizi D. The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol. 1984 Apr;132(4):1851–1857. [PubMed] [Google Scholar]
  5. Chouaib S., Fradelizi D. The mechanism of inhibition of human IL 2 production. J Immunol. 1982 Dec;129(6):2463–2468. [PubMed] [Google Scholar]
  6. Dahlberg P. A., Karlsson F. A., Lindström B., Wide L. Studies of thyroid hormone and methimazole levels in patients with Graves' disease on a standardized anti-thyroid drug regimen. Clin Endocrinol (Oxf) 1981 Jun;14(6):555–562. doi: 10.1111/j.1365-2265.1981.tb02965.x. [DOI] [PubMed] [Google Scholar]
  7. Eisenstein Z., Engelsman E., Weiss M., Kalechman Y., Sredni B. Production of and response to interleukin-2 in Graves' disease. J Clin Immunol. 1988 Sep;8(5):349–355. doi: 10.1007/BF00917150. [DOI] [PubMed] [Google Scholar]
  8. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  9. Gearing A. J., Johnstone A. P., Thorpe R. Production and assay of the interleukins. J Immunol Methods. 1985 Oct 24;83(1):1–27. doi: 10.1016/0022-1759(85)90053-5. [DOI] [PubMed] [Google Scholar]
  10. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  11. Goldrath N., Eisenstein Z., Bank H., Shoham J. Anti-thyroid drugs and lymphocyte function. I. The in vitro effect on blastogenesis and suppressor cell activity. Clin Exp Immunol. 1982 Oct;50(1):55–61. [PMC free article] [PubMed] [Google Scholar]
  12. Goldrath N., Shoham J., Bank H., Eisenstein Z. Anti-thyroid drugs and lymphocyte function. II. The in vivo effect on blastogenesis and suppressor cell activity in Graves' disease. Clin Exp Immunol. 1982 Oct;50(1):62–69. [PMC free article] [PubMed] [Google Scholar]
  13. Huang Y. P., Miescher P. A., Zubler R. H. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol. 1986 Dec 1;137(11):3515–3520. [PubMed] [Google Scholar]
  14. Kaneoka H., Morito F., Yamaguchi M. Low responsiveness to the anti Leu 4 antibody by T cells from patients with active systemic lupus erythematosus. J Clin Lab Immunol. 1989 Jan;28(1):15–26. [PubMed] [Google Scholar]
  15. Kawabe Y., Eguchi K., Shimomura C., Mine M., Otsubo T., Ueki Y., Tezuka H., Nakao H., Kawakami A., Migita K. Interleukin-1 production and action in thyroid tissue. J Clin Endocrinol Metab. 1989 Jun;68(6):1174–1183. doi: 10.1210/jcem-68-6-1174. [DOI] [PubMed] [Google Scholar]
  16. Koizumi T., Nakao Y., Matsui T., Katakami Y., Nakagawa T., Fujita T. Synergistic induction by calcium ionophore and phorbol ester of interleukin-2 (IL-2) receptor expression, IL-2 production, and proliferation in autoimmune MRL/MP-lpr mice. Immunology. 1986 Sep;59(1):43–49. [PMC free article] [PubMed] [Google Scholar]
  17. Kumagai N., Benedict S. H., Mills G. B., Gelfand E. W. Requirements for the simultaneous presence of phorbol esters and calcium ionophores in the expression of human T lymphocyte proliferation-related genes. J Immunol. 1987 Sep 1;139(5):1393–1399. [PubMed] [Google Scholar]
  18. Linker-Israeli M., Bakke A. C., Kitridou R. C., Gendler S., Gillis S., Horwitz D. A. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol. 1983 Jun;130(6):2651–2655. [PubMed] [Google Scholar]
  19. Magilavy D. B., Rowley D. A., Davis M. The liver of MRL/lpr mice contains defective accessory cells and a population of immunosuppressive lymphocytes. Cell Immunol. 1990 Feb;125(2):469–479. doi: 10.1016/0008-8749(90)90100-6. [DOI] [PubMed] [Google Scholar]
  20. McGregor A. M., Petersen M. M., McLachlan S. M., Rooke P., Smith B. R., Hall R. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med. 1980 Aug 7;303(6):302–307. doi: 10.1056/NEJM198008073030603. [DOI] [PubMed] [Google Scholar]
  21. McMurry J. F., Jr, Gilliland P. F., Ratliff C. R., Bourland P. D. Pharmacodynamics of propylthiouracil in normal and hyperthyroid subjects after a single oral dose. J Clin Endocrinol Metab. 1975 Aug;41(2):362–364. doi: 10.1210/jcem-41-2-362. [DOI] [PubMed] [Google Scholar]
  22. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  23. Murakawa Y., Takada S., Ueda Y., Suzuki N., Hoshino T., Sakane T. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol. 1985 Jan;134(1):187–195. [PubMed] [Google Scholar]
  24. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 1984 Apr 19;308(5961):693–698. doi: 10.1038/308693a0. [DOI] [PubMed] [Google Scholar]
  25. Papic M., Stein-Streilein J., Zakarija M., McKenzie J. M., Guffee J., Fletcher M. A. Suppression of peripheral blood natural killer cell activity by excess thyroid hormone. J Clin Invest. 1987 Feb;79(2):404–408. doi: 10.1172/JCI112826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tilden A. B., Balch C. M. A comparison of PGE2 effects on human suppressor cell function and on interleukin 2 function. J Immunol. 1982 Dec;129(6):2469–2473. [PubMed] [Google Scholar]
  27. Ting C. C., Yang S. S., Hargrove M. E. Induction of suppressor T cells by interleukin 2. J Immunol. 1984 Jul;133(1):261–266. [PubMed] [Google Scholar]
  28. Truneh A., Albert F., Golstein P., Schmitt-Verhulst A. M. Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature. 1985 Jan 24;313(6000):318–320. doi: 10.1038/313318a0. [DOI] [PubMed] [Google Scholar]
  29. Tötterman T. H., Karlsson F. A., Bengtsson M., Mendel-Hartvig I. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med. 1987 Jan 1;316(1):15–22. doi: 10.1056/NEJM198701013160104. [DOI] [PubMed] [Google Scholar]
  30. Volpé R. Immunoregulation in autoimmune thyroid disease. N Engl J Med. 1987 Jan 1;316(1):44–46. doi: 10.1056/NEJM198701013160109. [DOI] [PubMed] [Google Scholar]
  31. Weetman A. P. Effect of the anti-thyroid drug methimazole on interleukin-1 and interleukin-2 levels in vitro. Clin Endocrinol (Oxf) 1986 Aug;25(2):133–142. doi: 10.1111/j.1365-2265.1986.tb01674.x. [DOI] [PubMed] [Google Scholar]
  32. Zier K. S., Leo M. M., Spielman R. S., Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes. 1984 Jun;33(6):552–555. doi: 10.2337/diab.33.6.552. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES